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Background: Cyclic phosphatidic acid (cPA) is a structural analog of lysophosphatidic acid (LPA), but possesses
different biological functions, such as the inhibition of autotaxin (ATX), an LPA-synthesizing enzyme. As LPA is a
signaling molecule involved in nociception in the peripheral and central systems, cPA is expected to possess
analgesic activity. We characterized the effects of cPA and 2-carba-cPA (2ccPA), a chemically stable cPA analog, on
acute and chronic pain.
Results: (1) The systemic injection of 2ccPA significantly inhibited somato-cardiac and somato-somatic C-reflexes
but not the corresponding A-reflexes in anesthetized rats. (2) 2ccPA reduced sensitivity measured as the paw
withdrawal response to electrical stimulation applied to the hind paws of mice through the C-fiber, but not Aδ or
Ab. (3) In mice, pretreatment with 2ccPA dose-dependently inhibited the second phase of formalin-induced licking
and biting responses. (4) In mice, pretreatment and repeated post-treatments with 2ccPA significantly attenuated
thermal hyperalgesia and mechanical allodynia following partial ligation of the sciatic nerve. (5) In rats, repeated
post-treatments with 2ccPA also significantly attenuated thermal hyperalgesia and mechanical allodynia following
chronic sciatic nerve constriction.
Conclusions: Our results suggest that cPA and its stable analog 2ccPA inhibit chronic and acute inflammation-
induced C-fiber stimulation, and that the central effects of 2ccPA following repeated treatments attenuate
neuropathic pain.
2. Background
Cyclic phosphatidic acid (cPA) was originally isolated
from myxoamoebae of a true slime mold, Physarum
polycephalum, in 1992 [1]. The chemical formula of
cPA is similar to that of lysophosphatidic acid (LPA),
but cPA has a unique structure with a cyclic phosphate
ring at sn-2 and sn-3 of the glycerol backbone [2].
These features provide cPA with distinct/opposing bio-
logical functions from those of LPA. For instance, LPA
stimulates cell proliferation and cancer cell invasion,
while cPA inhibits these activities [3-8]. Interestingly,
LPA is enzymatically generated from
transphosphatidylation of lysophosphatidylcholine by
autotaxin (ATX) [9], but cPA inhibits ATX activity [10].
Thus, cPA could be an endogenous inhibitor of LPA
production through ATX.
Exogenous and endogenous LPA cause acute pain
through C-fibers and neuropathic pain [11-13]. Recent
studies revealed that nerve injury-induced LPA produc-
tion and neuropathic pain were significantly attenuated
in mice with heterozygous ATX deficiency [14,15]. In
this study, we characterized the effects of cPA and its
chemically stable analog 2ccPA on acute and neuro-
pathic pain.
3. Methods
3.1. Recording the somato-cardiac sympathetic reflex
The experiments were performed using male Wistar rats
(n = 11) weighing 270-370 g anesthetized by
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any medium, provided the original work is properly cited.intraperitoneal (i.p.) application of urethane (1.1 g/kg). A
femoral vein was catheterized for intravenous (i.v.)
administration of supplemental anesthetics and cPA. A
femoral artery was catheterized to record arterial blood
pressure and heart rate. The animals were immobilized
by gallamine triethiodide (20 mg/kg i.v. as required) and
artificially ventilated via tracheal cannula. Ventilation
was monitored with a gas analyzer (1H26; NEC San-ei,
Tokyo) and adjusted to maintain an end-tidal CO2 level
of 3.0%. Body temperature was maintained at 37.5°C
using an automatically regulated heating pad and lamp
(ATB-1100; Nihon Kohden, Tokyo). Both vagal nerves
were cut at the cervical level to prevent vagal contami-
nation of the recorded sympathetic nerve activity.
With the rat placed in the supine position, the right
second costal bone was removed. The right inferior car-
diac sympathetic nerve was dissected retropleurally, cut
as close to the heart as possible, and covered with warm
paraffin oil. Cardiac sympathetic efferent nerve activity
was recorded from the central segment of the cardiac
sympathetic nerve with platinum-iridium wire electrodes
using an AC preamplifier (S-0476; Nihon Kohden,
Tokyo; time constant set at 0.33 s). Reflex responses eli-
cited by electrical stimulation of a hind limb nerve were
averaged (50 trials) by a computer (ATAC 3700; Nihon
Kohden, Tokyo or UPO, Unique Medical, Tokyo). The
averaged responses were stored as digital signals and
recorded on a printer or mini-writer. The size of the
reflex response was measured as the area under the
evoked response and expressed as the percent of the
control size preceding drug injection.
A tibial nerve was dissected from the surrounding tis-
sues and cut. The central cut end segment of the nerve
was placed on bipolar platinum-iridium wire electrodes
for electrical stimulation. Single square pulse stimuli of
0.5 ms duration were delivered every 3 s by a digital
electrical stimulator (SEN-7103; Nihon Kohden, Tokyo).
3.2. Recording spinal somato-somatic reflex
Male Wistar rats (n = 4; weighing 330-350 g) were
anesthetized using pentobarbital (50 mg/kg i.p.). A jugular
vein was catheterized for i.v. administration of cPA. Body
temperature was maintained at 37.5°C. The spinal cord
was completely transected at the upper thoracic level.
With the rat placed in the supine position, a branch of
the right saphenous nerve innervating thigh skin was cut
at the thigh level. The central cut end segment of the
nerve was stimulated electrically as described above.
Electromyogram (EMG) was recorded from the right leg
muscles by inserting silver electrodes using the AC pre-
amplifier. With single shocks, post-stimulus time histo-
grams were created by a computer (ATAC 3700; Nihon
Kohden, Tokyo) for EMG activity for approximately 50
trials at 3-s intervals. The averaged responses were
stored as digital signals andr e c o r d e do nam i n i - w r i t e r .
The size of the reflex response was measured as the
area under the evoked response and expressed as the
percent of the control size preceding drug injection.
3.3. Electrical stimulation-induced paw withdrawal (EPW)
Test
Male C57BL/6 mice (TEXAM, Japan) weighing 18-22 g
were used. The electrical stimulation-induced paw with-
drawal (EPW) test conducted using the Neurometer™
CPT/C (Neurotron Inc.) has been reported previously
[16]. In brief, electrodes were fastened to the plantar
surface and instep of the mice. Transcutaneous nerve
stimuli with each of the 3 sine wave pulses (5, 250, and
2000 Hz) were applied using the Neurometer™.T h e
minimum intensity at which each mouse exhibited paw
withdrawal was defined as the current stimulus thresh-
old at 10-15 min after i.v. 2ccPA injection.
3.4. Formalin test
According to several preceding works [17,18] and to an
economical advantage, we used ICR (CD1) female mice
(Charles River, Japan), 6-9 weeks of age for the formalin
test. Formalin solution (30 μL, 2% v/v) in saline was
subcutaneously (s.c.) injected into the plantar surface of
the left hind paw. Immediately after the formalin injec-
tion, the animals were placed in a cage and videotaped
for 30 min from beneath the transparent floor. The time
(in seconds) spent licking and biting the injected paw
was counted in 5-min intervals by videotape observa-
tion. Two distinct phases of intensive licking and biting
activities identified as the early and late phases were
defined at 0-10 min and 10-30 min, respectively. At 3
min before formalin was injected, 2ccPA solution (in
PBS containing 1% BSA) was i.v. injected. Morphine
hydrochloride solution (Takeda Pharmaceutical Com-
pany, Osaka, Japan) in saline was i.p. injected at 30 min
before formalin injection.
3.5. Neuropathic pain models
In experiments using the C57BL/6 mice, partial ligation
of the sciatic nerve was performed under pentobarbital
(50 mg/kg) anesthesia, following the methods of Malm-
berg and Basbaum [19]. 2ccPA was dissolved in artificial
cerebrospinal fluid (aCSF: 125 mM NaCl, 3.8 mM KCl,
1.2 mM KH2PO4, 26 mM NaHCO3, 10 mM glucose, pH
7.4). The intrathecal injection (i.t.) of 2ccPA was given
into the space between spinal L5 and L6 segments
according to the method of Hylden and Wilcox [20]. In
the thermal paw withdrawal tests, nociception was mea-
sured as the latency to paw withdrawal evoked by expo-
sure to a thermal stimulus [21,22]. Unanesthetized
animals were placed in Plexiglas cages on the top of a
glass sheet and were allowed an adaptation period of 1
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USA) was positioned under the glass sheet, and the
focus of the projection bulb was aimed precisely at the
middle of the plantar surface of the animal. A mirror
attached to the stimulator permitted plantar surface
visualization. The paw pressure test was performed, as
described previously [22]. Mice were placed into a Plexi-
glas chamber on a 6 × 6 mm wire-mesh grid floor and
allowed to acclimatize for 1 h. A mechanical stimulus
was delivered onto the middle of the plantar surface of
the right hind paw using a Transducer Indicator (Model
1601; IITC Inc., Woodland Hills, CA, USA). The pres-
sure needed to induce a flexor response was defined as
the pain threshold.
In experiments using rats, the chronic constriction
injury was produced according to the procedure of Ben-
nett and Xie [23]. Briefly, rats (182-216 g at day of liga-
tion) were anesthetized with sodium pentobarbital
(Nembutal, Dainippon pharmaceutical co., 40 mg/kg i.
p.). The left sciatic nerve was exposed at mid-thigh
level. Three loose ligatures with 4.0 chromic gut (SG-
535; Syneture, USA), about 1-mm spacing, were tied
around the sciatic nerve proximal to the trifurcation. Six
days after nerve ligation, the development of neuropathy
was assessed by measuring paw withdrawal latencies
against thermal and mechanical stimuli [24,25]. Briefly,
the thermal withdrawal threshold of a hind paw was
measured using a beam of radiant infrared heat and a
photocell (Planter Test model 7370; Ugo Basil, Milan,
Italy). To prevent tissue damage, the cut-off time was
set to 20 or 30 sec for rats with or without ligation. The
mechanical withdrawal threshold was measured by the
von Frey filament test. All rats were administered drug
treatment by i.v. injection, and experiments were per-
formed at 10 min and at 2 and 4 hours after drug
treatments.
3.6. Drugs
We used chemically synthesized cPA 18:1 and its biolo-
gically stable derivative, 2-carba cPA 16:1 (2ccPA) (Fig-
ures 1A, B) [6]. These compounds were i.v. or i.t
administered after they were dissolved in saline or artifi-
cial cerebrospinal fluid (aCSF).
3.7. Statistical analysis
Data were expressed as mean ± S.E. The data were sta-
tistically analyzed by Student’st - t e s t ,W e l c h ’st e s t ,
Steel’st e s t ,D u n n e t t ’s test, Wilcoxon test, or Tukey’s
multiple comparison tests. A P value < 0.05 was consid-
ered statistically significant.
3.8. Ethical approval
All the experiments were performed with an approval of
the Animal Care and Use Committee at the Tokyo
Metropolitan Institute of Gerontology and Nagasaki
University Animal Care Committee at the Nagasaki Uni-
versity Graduate School of Biomedical Sciences (refer-
ence number 0706130596).
4. Results
4.1. Effects of cPA and 2ccPA on somato-cardiac
sympathetic A- and C-reflexes in anesthetized rats
Single shock stimulation of A- and C-afferent fibers of
the tibial nerve (at 10 V with 0.5 ms pulse duration) eli-
cited 2 types of cardiac sympathetic reflex discharges as
shown in Figure 2A. These discharges occur in a short
latency (about 40 ms) as the A-sympathetic reflex and
in a long latency (about 210 ms) as the C-sympathetic
reflex, respectively (Figure 2A).
Intravenous injection of 0.1 mg/kg of 2ccPA depressed
the C-reflex but not the A-reflex (Figure 2A). In most
experiments, the 2ccPA-induced depression of C-reflex
components started several minutes after the injection,
reached its maximum level in less than 15 min, and
then gradually returned to baseline within 40 min. The
response was reproducible in successive trials on the
same animal. Injection of 2ccPA 18:1 also yielded simi-
lar C-reflex suppression (data not shown).
Figure 2B summarizes the effects of i.v. injection of
2ccPA and cPA on the C-reflex in 8 rats. The responses
were measured at 10-15 min after i.v. injection of cPA,
i.e., after reaching the maximum effect (see above).
After injection of 0.2 mg/kg 2ccPA, the C-reflex reached
82 ± 9% of the control. Injection of 2 mg/kg, but not
0.2 mg/kg cPA, significantly depressed the C-reflex.
Figure 1 Structure of cPA and 2ccPA. A naturally occurring
derivative (A; cPA 18:1) and a chemically synthesized derivative used
for the present experiments (B; 2ccPA 16:1).
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± 8% of the control.
4.2. Effects of cPA and 2ccPA on somato-somatic A- and
C-reflexes in anesthetized rats
The hypothesis that cPA acts at the primary afferent
nerve terminals was tested by recording spinal somato-
somatic reflexes in 4 rats (Figure 3). Stimulation of the
myelinated A-afferent fibers and unmyelinated C-affer-
ent fibers of the saphenous nerve (at 15 V with 0.5 ms
pulse duration) produced 2 distinct A- and C-somatic
reflex components in the hind limb EMG, i.e., a short
latent (about 10 ms) A-reflex and long latent (about 70
ms) C-reflex. Intravenous application of the same 2ccPA
dose (0.2 mg/kg) that depressed the somato-sympathetic
C-reflex also depressed the C-somatic reflex component
to a similar magnitude. After injection of 0.2 mg/kg
2ccPA, the C-reflex reached 83 ± 5% (n = 4) of the con-
trol (p < 0.05).
4.3. C-fiber specific analgesic effects of 2ccPA on
electrical stimulation-induced paw withdrawal (EPW)
We established the EPW test to distinguish responses
mediated by different sensory fibers [16]. The hind paw
is given transcutaneous nerve stimuli with sine-wave
pulses of 5, 250, or 2000 Hz to stimulate C-, Aδ-, or
Ab-fibers [26,27], and the intensity (μA) required to
induce a withdrawal reflex was defined as the threshold.
The thresholds of naïve mice for 5, 250, and 2000 Hz
stimuli were 64.4 ± 1.9 (C-fibers), 145.0 ± 4.5 (Aδ-
fibers), and 401.1 ± 13.6 (Ab-fibers). When the EPW
test was performed at 10-15 min after the 2ccPA (i.v.)
injection, the threshold increased in a dose-dependent
manner with 5 Hz, but it did not increase with 250- or
2000-Hz stimuli (Figure 4).
Figure 2 Effects of i.v. cPA and 2ccPA on somato-cardiac
sympathetic A- and C-reflexes. A, Specimen records of A- and C-
reflexes (averages of 50 trials) elicited by single electrical stimulation
of a tibial nerve using 10 V of stimulus strength. Left: prior to 2ccPA
application (control). Right: 15 min after i.v. injection of 0.1 mg/kg
2ccPA. B, Graphical summary of the size of the C-reflex at 0-5 min
before cPA/2ccPA injection (control; n = 8), at 10-15 min after i.v.
injection of 0.2 mg/kg 2ccPA (n = 4), and 0.2 mg/kg (n = 4) and 2
mg/kg (n = 4) cPA. We averaged 1-2 trials for each rat. The mean
size (area under the evoked response curve) of the C-reflex at 0-10
min before each injection was expressed as 100%. All subsequent
reflexes were expressed as percentages of the control values. Each
column and vertical bar represent mean and S.E. *P < 0.05;
significantly different from the control response by Student’s t-test.
Figure 3 Effects of i.v. 2ccPA on the somato-somatic C-reflex.
A, Specimen records of A- and C-reflexes (averages of 50 trials)
elicited by single electrical stimulation of a saphenous nerve using
15 V of stimulus strength. Left: prior to 2ccPA application (control).
Right: 10 min after i.v. injection of 0.2 mg/kg 2ccPA.B, Graphical
summary of the size of the C-reflex at 0-5 min before 2ccPA
injection (control; n = 4) and at 10-15 min after i.v. injections of 0.2
mg/kg 2ccPA (n = 4). We averaged 1-2 trials for each rat. The mean
size (area under the evoked response curve) of the C-reflex at 0-10
min before each injection was expressed as 100%. All subsequent
reflexes were expressed as percentages of the control values. Each
column and vertical bar represent mean and S.E. *P < 0.05;
significantly different from the control response by Student’s t-test.
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licking and biting behavior
In the formalin-induced nociception tests, ICR (CD1)
mice were given an s.c. injection of formalin solution to
the hind paw. As shown in Figure 5A, the time course
of the total time spent in licking and biting comprised 2
phases. Morphine or i.v. injection of 2ccPA at 30 min
prior to formalin injection markedly reduced phase II
licking and biting. Quantitative analysis revealed that
2ccPA exerted dose-dependent inhibition of phase II
responses, with significant inhibition observed at a 10-
mg/kg i.v. dose (Figure 5B). As a reference, significant
analgesia was also achieved with 3 mg/kg morphine.
4.5. Pre-injury administration of 2ccPA prevents
neuropathic pain development
LPA is produced by ATX in the early phase after nerve
injury [13,14]; therefore, we administered 2ccPA (10
nmol, i.t. or 100 nmol, i.t.) at 30 min prior to inducing
nerve injury. 2ccPA prevented thermal hyperalgesia and
mechanical allodynia in a dose-dependent manner at 5
and 7 days after nerve injury (Figure 6). However,
2ccPA (i.t.) injection in naïve C57BL/6 mice had no sig-
nificant effect on nociceptive latency at 90 min or 1 or
7 days after injection (additional file 1).
4.6. Repeated administration of 2ccPA induces analgesia
against established neuropathic pain in mice
We examined the effects of 2ccPA on established neuro-
pathic pain in C57BL/6 mice. In the thermal withdrawal
test, mice with sciatic nerve injury exhibited a decreased
threshold at day 7. Under these conditions, a single
2ccPA dose (100 nmol, i.t.) significantly increased
nociceptive latency at 30 min on the day 7 after injury
(considered as day 1), as shown in Figure 7Ba. When
2ccPA (i.t.) was administered daily to the injured mice,
the basal latency (before the i.t. injection) time-depen-
dently increased from day 1 to 7, though no significant
change was observed on the 7th day (Figures 7Ba-d). A
significant increase was observed at 90 min after the
2ccPA injection on the day 4 and at all time points until
120 min on the 7th day (Figure 7Bc). The reason for
more pronounced 2ccPA analgesia on the 7th day may
be attributed to the fact that there is some, but not sig-
nificant increase in the basal latency on the 7th day. A
single 2ccPA injection (10 mg/kg i.v.) had no effect on
thermal hyperalgesia (Figure 7Ca). There was significant
analgesia by 2ccPA (i.v.) on the seventh day following
daily injections (i.v.), with no change in basal latency
throughout the 7 days (Figures 7Ca-d).
In the paw-pressure test, repeated post-injection (i.t.
or i.v.) of 2ccPA yielded similar effects on day 8 (Figure
8). Following repeated i.t. injection, there was an
increasing trend in basal latency on day8, while there
was no change with i.v. injection. Significant analgesia
was also observed at several time points after the 2ccPA
i.t. injection but not after the i.v. injection. When the
area under the curve (AUC) was evaluated, there was
significant analgesia with both i.t. and i.v. injections on
day 8 (Figure 8D).
4.7. Repeated 2ccPA administration induces analgesia
against established neuropathic pain in rats
Similar studies to examine the analgesic effects of 2ccPA
against established chronic pain were performed using a
different chronic-pain model in rats. In the chronic
Figure 4 Effects of cPA on the Electrical Stimulation-Induced Paw Withdrawal (EPW) test. The threshold represents the minimum intensity
(μA) required to elicit a paw withdrawal response to electrical stimulation with 5 Hz (C-fiber) (A), 250 Hz (Aδ-fiber) (B), and 2000 Hz (Ab-fiber) (C).
The EPW test was performed 10-15 min after 2ccPA (i.v.) injection. All data represent the mean ± S.E. from 3-6 individual mice per group. *P <
0.05; significantly different from the control response by Tukey’s multiple comparison.
Kakiuchi et al. Molecular Pain 2011, 7:33
http://www.molecularpain.com/content/7/1/33
Page 5 of 11constrictive sciatic nerve injury (CCI) model, the same
experimental schedule was performed, as described
above (Figure 9). In the thermal withdrawal test, there
was significant analgesia at 2 h after i.v. injection of
2ccPA (10 mg/kg) on the seventh day following repeated
injections, with no significant change in the basal
latency at time 0 min (Figure 9B). There was weak but
not significant analgesia at 2 h with 3 mg/kg (i.v.) on
the seventh day (Figure 9C), while significant analgesia
was observed on the fourth day with 10 mg/kg (Figure
9D). The 2ccPA-induced analgesia was slightly weaker,
but comparable to the analgesic effects of gabapentin
(90 mg/kg i.v.). Similar results were observed with the
paw-pressure test (Figures 9E-9G). In this case, weak
but significant analgesia against mechanical allodynia
was observed only with 10 mg/kg at 4 h on the seventh
day. However, the analgesic effect was much lower than
that with gabapentin.
5. Discussion
We designed and chemically synthesized the metaboli-
cally stabilized derivatives of cPA, to avoid cPA hydroly-
sis in animals [10]. In 2ccPA, the phosphate oxygen of
cPA is replaced with a methylene group at sn-2 (Figure
1). This study showed that the effective dose of 2ccPA
was almost 10-fold less than that of natural cPA, consis-
tent with other studies [6,7,10]. Differences in chemical
stability and/or structural traits might account for the
difference in the effective dose of natural cPA and
2ccPA required to achieve analgesia. The specificity of
these compounds has been extensively reported [7,10].
Our initial examination demonstrated that intragastral
administration of 1 mg/kg of 2ccPA resulted in a
remarkable 40% reduction of the somato-cardiac sympa-
thetic C-reflex (additional file 2), suggesting practical
stability against gastric digestion as well as rapid gastric
absorption of 2ccPA. We examined another carba-cPA,
3ccPA, in which the phosphate oxygen of cPA is
replaced with a methylene group at sn-3, and found that
effective doses of 3ccPA 16:1 were similar to those of
2ccPA for suppression of somato-cardiac sympathetic
reflexes (additional file 3). In this report, we demon-
strated that cPA and 2ccPA suppressed the supraspinal
sympathetic and spinal kinetic reflexes, specifically the
C-fiber, but not the A-fiber reflex, in anesthetized ani-
mals. This result was consistent with the experiments
with mice, in which 2ccPA increased the nociceptive
threshold only for Neurometer™ electrical stimulus
with 5 Hz, which is supposed to stimulate C-fibers, but
not with 250 or 2000 Hz, which are supposed to stimu-
late Aδ and Ab-fibers [16]. These results suggest that
both cPA and 2ccPA suppress nociceptive responses by
primary afferent C-fibers. Both compounds are reported
to possess selective and potent ATX inhibitory activities
[10]. Endogenous LPA in the peripheral tissues or
plasma exerts tonic stimulation of C-fibers, as evidenced
by previous findings that LPA injected into the hind
paw of mice caused nociceptive flexor responses, par-
tially via substance P release from the nociceptor end-
ings of C-fibers [11,28]. As there was no significant
analgesia with i.t.-injected 2ccPA (additional file 1), the
inhibitory responses of these compounds are unlikely to
be mediated by inhibition of LPA synthesis in naïve
Figure 5 Effects of i.v. 2ccPA on licking and biting time. A, Time
variations of licking and biting time of mice s.c. injected with 30 μL
of 2% formalin in the mouse hind paw immediately after i.v.
injection with 10 mg/kg (closed triangle) 2ccPA or vehicle (open
circle). Morphine (3 mg/kg i.p.) was applied 30 min prior to formalin
injection as a control. Each data point represents the average licking
and biting time for 8-13 mice. B, Graphical summary of the total
phase I and II licking and biting times of mice at 1 mg/kg, 3 mg/kg,
or 10 mg/kg 2ccPA. All data represent the mean ± S.E. *P < 0.05;
significantly different from the control response by Student’s t-test.
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sciatic nerve injury in mice. 2ccPA (10 or 100 nmol/5 μL i.t.) was injected at 30 min prior to nerve injury. The threshold was measured on days
3, 5, and 7 after nerve injury, using the thermal withdrawal (A) and paw-pressure (B) tests. All data represent the mean ± S.E. from 3-6 individual
mice per group. *P < 0.05; significantly different from the control response by Tukey’s multiple comparison tests.
Figure 7 Repeated administrations of 2ccPA (i.v. or i.t.) induces analgesia against established thermal hyperalgesia in mice with
neuropathic pain. A, Neuropathic pain in mice was induced by partial sciatic nerve injury. Vehicle or 2ccPA (i.v. or i.t.) was injected daily for 7
days, starting 7 days after injury. B, Vehicle or 2ccPA (100 nmol/5 μL 1-3 days and 10 nmol/5 μL 4-7 days, respectively, i.t.) was daily injected for 7
days, starting 7 days after injury. The withdrawal latency was measured at 30, 60, 90, and 120 min after the injection of 2ccPA (i.t.) on the first (a),
fourth (b), or seventh day (c). The basal latency was measured before injection of 2ccPA (i.t.) (d). (C) Vehicle or 2ccPA (10 mg/kg, i.v.) was daily
injected for 7 days, starting 7 days after injury. The withdrawal latency was measured at 30, 60, 90, and 120 min after the injection of 2ccPA (i.v.) on
the first (a), fourth (b), or seventh day (c). The basal latency was measured before injection of 2ccPA (i.t.) (d). All data represent the mean ± S.E. from
3-6 individual mice per group. *P < 0.05 indicates significant difference from the vehicle response by Tukey’s multiple comparison test.
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cPA and/or 2ccPA may have inverse agonist actions on
C-fiber nociceptor endings, since they have some weak
actions on LPA receptors [7,10].
We also found that 2ccPA exerted anti-nociceptive
effects in the formalin test. Formalin-induced character-
istic behaviors in phase I are the result of direct C-fiber-
evoked excitation, whereas the behaviors in phase II are
evoked by repetitive C-fiber stimulation [29,30]. 2ccPA
reduced both phase responses, but the inhibition of
phase II responses was significant. We speculate that
repetitive C-fiber stimulation may cause the ATX-cata-
lyzed production of LPA in the periphery and stimulate
C-fibers in an autocrine manner.
It should be noted that 2ccPA attenuated neuropathic
pain possibly via the central nervous system. Our initial
study revealed that i.t. injection of 2ccPA prevented
nerve injury-induced neuropathic pain in mice. This
finding is consistent with a series of studies by Ueda
and colleagues, in which nerve injury induces LPA pro-
duction by ATX in the spinal cord and causes neuro-
pathic pain through the LPA1 receptor [12,13,31]. The
most striking evidence is that repeated administration
of 2ccPA through i.t. and i.v. routes produced signifi-
cant analgesia against established neuropathic pain in
mice and rats. The i.t. injection of 2ccPA on day 7 after
injury produced weak analgesia against thermal
hyperalgesia. More pronounced analgesia was observed
when it was given daily by the seventh i.t. injection on
day 13 after injury. As there is some, but not significant,
recovery of the basal threshold before the seventh injec-
tion of 2ccPA, LPA production may occur in the late
phase to maintain the neuropathic pain status, as well
as at the early phase to trigger the initiating mechan-
isms [12]. Similar analgesic effects were observed with i.
v. injection by the seventh injection on day 13 after
injury, though there was no tendency to recover the
basal threshold. The difference of basal latency follow-
ing repeated injections between i.t. and i.v. routes may
be related to the fact that there are some residual
increases at as late as 120 min in the case with i.t., but
not i.v. injections at the 1st and 4th day. Although the
lack of elevation in the basal threshold cannot be
explained at this time, it seems to occur after repeated
i.v. treatments: i.v.-injected 2ccPA-induced analgesia
was equivalent to that yielded by the first i.t. injection.
We previously reported that cPA and carba derivatives
penetrate into the central nervous system through the
blood-brain barrier [32]. In the present study, the effec-
tive dosage of 2ccPA for mice were about five times
higher than that for rats, both for i.v. and i.p. injection,
possibly because these two animals exhibit different sen-
sitivities against administered drugs depending on their
chemical species [33].
Figure 8 Repeated administration of 2ccPA (i.v. or i.t.) induces analgesia against established mechanical allodynia in neuropathic pain
mice. Vehicle or 2ccPA (10 mg/kg i.v.) was daily injected for 8 days, starting 7 days after injury (A). The threshold in the paw pressure test was
measured at 30, 60, 90, 120, 150, and 180 minutes after 2ccPA application (i.t. or i.v.) on the eighth day (B and C). Quantitative analyses with
2ccPA (i.t. or i.v.) were performed with the area under the curve (AUC) (D). AUC data represent increased thresholds by subtracting the
thresholds before injection in vehicle-treated mice. All data represent the mean ± S.E. from 3-6 individual mice per group. *P < 0.05 indicates
significant difference from the vehicle response by Tukey’s multiple comparison test.
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tion; i.t. injection of LPA or the addition of LPA to spinal
cord slices markedly increased the LPA level in a time-
dependent manner with the peak occurring at 3 h [14,34].
This finding indicates the presence of feed-forward ampli-
fication of LPA production in initiating neuropathic pain.
As LPA production declines, however, there may be end-
product inhibition. Although it is a fascinating mechanism
that cPA is a natural ATX inhibitor [10] produced by
ATX, it remains to be seen whether the amounts of cPA
produced are sufficient to exert this effect.
6. Conclusion
Our results indicate that cPA and 2ccPA are potent
inhibitors of nociceptive transmission by C-primary-
afferents and reverse inflammatory and neuropathic
pain. These chemicals may be good candidates for use
in clinical pain management.
Figure 9 Effects of i.v. 2ccPA on thermal paw-withdrawal and mechanical allodynia of nerve-ligated rats. A, The rat sciatic nerve was
ligated 7 days prior to i.v. injection of 2ccPA, applied once daily for 7 consecutive days. B, A hind paw was irradiated with infrared light to
evoke thermal withdrawal, and the time variation of the withdrawal latency was measured prior to and at 10 min, 2 h, or 4 h after the
application of 2ccPA on the seventh day. C, Dose response; 2-h injection of 2ccPA at 3 or 10 mg/kg applied once daily for 7 consecutive days.
D, Time course; 2-h injection of 2ccPA (10 mg/kg) applied once daily for 4 or 7 consecutive days. Gabapentin (90 mg/kg i.v.) was applied as a
control. *P < 0.05 and #P < 0.05 indicates significant difference from the vehicle response by Dunnett’s test and by Student’s t-test or Welch’s
test, respectively. E, The responses of rats to tactile stimulation was tested with 5 von Frey filaments, and threshold filament sizes to evoke paw
withdrawal were measured prior to and at 10 min, 2 h, or 4 h after application of 2ccPA on the seventh day. F, Dose response; 4-h injection of
2ccPA at 1, 3 or 10 mg/kg applied once daily for 7 consecutive days. G, Time course; 4-h injection of 2ccPA (10 mg/kg) applied once daily for 4
or 7 consecutive days. Gabapentin (90 mg/kg i.v.) was applied as a control. *P < 0.05 and #P < 0.05 indicates significant difference from the
vehicle response by Steel’s test and by Wilcoxon test, respectively.
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Additional file 1: No effect of 2ccPA (i.t.) injection in naïve mice. The
thresholds were measured at 90 min (A) and on days 1 and 7 (B) after
2ccPA injection, using the thermal withdrawal test. All data represent the
mean ± S.E. from 3-6 individual mice per group.
Additional file 2: Time variation of relative C-reflex level after oral
administration of 2ccPA (16:1). Relative C-reflex levels were measured
after oral administration of 2ccPA (16:1) at 1 mg/kg and plotted over
time until 120 min. Each data point represents the average four
independent measurements, and vertical bar represents S.E. **P < 0.01
and *P < 0.05; significantly different from time 0 by one-way ANOVA,
Dunnett’s multiple comparison test.
Additional file 3: Effects of i.v. 3ccPA on the somato-carcdiac C-
reflex. Relative C-reflex levels of the somato-cardiac response were
measured after i.v. injection of 3ccPA (18:1) at 100 μg/kg (n = 3). Vertical
bar represents S.E. **P < 0.01; significantly different from the vehicle by
Student’s t-test.
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